Chapter 19 – Strategic Performance Measurement: Investment Centers
19–84
19–57 Transfer Pricing; Strategy (45–50 minutes)
1. At first glance, the overall strategy seems to be one of cost leadership,
due to the competitive conditions in the global market and the
competitive cost and price reductions referred to in the case. However,
there does not appear to be an important element of differentiation due
to quality or innovation within the industry. This is a medical products
company and it is reasonable to expect that customers will be looking for
reliability and functionality as key values of the products. Perhaps we
have here an example of the “confrontation” type of strategy as
described by Cooper (re: target costing in Chapter 13). Alternatively, we
might view the competition by product line. Some of the firm’s products
may be very commodity-like in nature, and cost/price competition is how
the firm has and will continue to be successful for these products. But for
other products, differentiation will continue to be the key success
strategy.
From a manufacturing standpoint, the firm is moving part of
manufacturing overseas to reduce overall product cost – taking
advantage of lower wage costs in some countries. This is very
consistent with the overall strategy, and makes sense given the
commodity-like nature of the firm’s products.
more of their health care needs. Also, a strategy to increase sales
worldwide would be more consistent with BLP’s competitive strategy of
cost leadership. Growth in sales will facilitate the economies of
production and distribution which are desirable in the cost-leadership
strategy.